Craniosynostosis syndromes are frequently associated with mutations in fibroblast growth factor receptors (FGFR2 or FGFR3) which play an important role in bone growth, particularly during embryonic development and are complexed with ECM components. This evidence concerns the gene FGFR2 and syndromic craniosynostosis.